A Case control study to determine Macrophage migration inhibitor, and N-telopeptides of type I bone collagen Levels in the sera of osteoporosis patients

Main Article Content

Layla Othman Farhan
Ekhlass M. Taha
Ahlam M. Farhan


This study focused on determining the markers of Macrophage migration inhibitor (MIF), as well as the N-telopeptides of type I bone collagen (NTX), and some other parameters (alkaline phosphatase (ALP), vitamin D (Vit D), calcium (Ca), phosphorus (P), and magnesium (Mg), and their correlation with other parameters in osteoporosis. One hundred ten subjects were involved in the current study. There were two groups of patients: group I (30) women with severe osteoporosis and group II (30) women with mild osteoporosis. For comparison, 50 apparently healthy individuals were included as a control. Serum levels of MIF, and NTX were significantly higher in groups I and II as compared to the control group, which indicate that these two parameters were related to disease. Moreover MIF, and NTX were organized in one cluster when applying cluster analysis test to all the studied groups. This indicates that in most of the studied samples the two parameters were related to each other as well as to osteoporosis.  Magnesium showed a significant decrease in its level in both groups as compared to the control. On the other hand, alkaline phosphatase (ALP) showed a significant increase in  its activity in both studied groups as compared to the control. Vitamin D level manifested significant difference between group I and group II, with a significant decrease in  its level when comparing group II with the control group.  The MIF, NTX was highly associated with osteoporosis patients, in addition to Mg and Vit-D. On the other hand, Ca and P levels did not alter in a significant way with osteoporosis which may be considered as a risk factor as long as they are organized in one cluster with MIF, NTX, Mg, and Vit D in all the studied patients. Both markers showed a clear cut-off value using the ROC curve in which the best cutoff value of NTX was 166.8 pg/ml, and the best cutoff value of MIF was 6.6 ng/ml according to ROC analysis. 


Download data is not yet available.

Article Details

How to Cite
Farhan LO, Taha EM, Farhan AM. A Case control study to determine Macrophage migration inhibitor, and N-telopeptides of type I bone collagen Levels in the sera of osteoporosis patients. Baghdad Sci.J [Internet]. 2022 Aug. 1 [cited 2023 Dec. 8];19(4):0848. Available from: https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/6221


Blackie R. Diagnosis, assessment and management of osteoporosis. Prescriber. 2020;31(1): 14–19.

Hong L, Liu D, Wu F, Wang M, Cen Y, Ma L. Correlation between Bone Turnover Markers and Bone Mineral Density in Patients Undergoing Long-Term Anti-Osteoporosis Treatment: A Systematic Review and Meta-Analysis. Appl. Sci. 2020;10(3): 832.

Ghudhaib KK, Turaki KM, Muzal SA. Estimation of Serum Osteocalcin Levels in Osteoporotic Postmenopausal Iraqi Women with Type 2 Diabetes Mellitus. Baghdad Sci. J. 2014;11(4).

Cavalli E, Ciurleo R, Petralia MC, Fagone P, Bella R, Mangano K, et al. Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets? Molecules. 2020;25(5): 1194.

Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F. Role of macrophage migration inhibitory factor (MIF) in melanoma. Cancers. 2019;11(4): 529.

Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu.Rev. Immunol. 2011;29: 415–445.

Hoi AY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets . 2007;6(3): 183–190.

Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. Front. immunol. 2015;6: 308.

Bucala R, Shachar I. The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. Mini Rev Med Chem. 2014;14(14): 1132–1138.

Basile MS, Battaglia G, Bruno V, Mangano K, Fagone P, Petralia MC, et al. The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration. Int J Mol. Sci. 2020;21(8): 3023.

Szulc P. Biochemical bone turnover markers and osteoporosis in older men: where are we? J osteoporos. 2011;( 2011) :5

Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin. Chem. 2008;54(1): 188–196.

Okano I, Salzmann SN, Ortiz Miller C, Rentenberger C, Schadler P, Sax OC, et al. Correlation between Urine N-Terminal Telopeptide and Fourier Transform Infrared Spectroscopy Parameters: A Preliminary Study. J osteoporos. 2020 (2020): 7.

Xie Z, Sun G, Chen L, Liu M, Qi D, Furey A, et al. Macrophage migration inhibitory factor may play a protective role in osteoarthritis. Arthritis Res Ther. 2021; 23(1):59.

Kim B-J, Lee SH, Koh J-M. Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures. Endocrinol Metab.2020;35(1): 55–63.

Nobre CCG, de Araújo JMG, de Medeiros Fernandes TAA, Cobucci RNO, Lanza DCF, Andrade VS, et al. Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. Pathol. Oncol. Res. 2017;23(2): 235–244.

Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: From pathogenic factors to therapeutic targets. Drug Discov Today. 2019;24(2): 428–439.

Kuo T-R, Chen C-H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5(1): 18.

Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin. Chem. 2017;63(2): 464–474.

Hashidate H, Kamimura M, Nakagawa H, Takahara K, Ikegami S, Uchiyama S, et al. Early changes in bone specific turnover markers during the healing process after vertebral fracture. Open Orthop J. 2011;5: 32.

Takahara K, Kamimura M, Hashidate H, Uchiyama S, Nakagawa H. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. J Orthop Sci . 2007;12(3): 219–226.

Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol . 2010;5(9): 1315–1316.

Aseel F K, Munawar AA, Nada AS. Ali HA.Biomarker significance of serum cxcl8, cxcl10 and cxcl16 in breast tumors of iraqi patients. Baghdad Sci. J. 2020;17(1) :199-206.